

Received: 2022.03.04

Accepted: 2022.03.04

Available online: 2022.03.04

Published: 2022.03.07

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

1 **Hao Song**
2 **Jinna Zhang**
3 **Liang Ning**
2 **Honglai Zhang**
3 **Dong Chen**
3 **Xuelong Jiao**
2 **Kejun Zhang**

1 Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, PR China

2 Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, PR China

3 Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, PR China

Corresponding Author: Kejun Zhang, e-mail: zkejun@yahoo.ca

Retraction Notice:

This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscript.

Reference:

Vemurafenib Hao Song, Jinna Zhang, Liang Ning, Honglai Zhang, Dong Chen, Xuelong Jiao, Kejun Zhang. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit, 2018; 24: 3002-3010. DOI: [10.12659/MSM.910084](https://doi.org/10.12659/MSM.910084)

